Login to Your Account

Abbvie strikes $595M deal for Boehringer anti-IL-23 MAb

By Michael Fitzhugh
Staff Writer

Monday, March 7, 2016

Abbvie Inc. agreed to pay Boehringer Ingelheim GmbH $595 million up front for the opportunity to co-develop and later sell BI 655066, a phase III anti-IL-23 monoclonal antibody for psoriasis that could eventually help Abbvie replace revenue losses that it will face as Humira begins to lose patent protection.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription